Get the Stockscreener App
96.91
1.72%
1.64
After Hours:
97.40
0.49
+0.51%
Incyte Corp stock is traded at $96.91, with a volume of 1.20M.
It is up +1.72% in the last 24 hours and up +2.77% over the past month.
Incyte focuses on the discovery and development of small-molecule drugs. The firm's leading drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes an array of oncology and dermatology programs.
See More
Previous Close:
$95.27
Open:
$95.26
24h Volume:
1.20M
Relative Volume:
0.72
Market Cap:
$19.36B
Revenue:
$5.36B
Net Income/Loss:
$1.43B
P/E Ratio:
13.70
EPS:
7.0718
Net Cash Flow:
$1.42B
1W Performance:
+2.39%
1M Performance:
+2.77%
6M Performance:
+3.67%
1Y Performance:
+56.23%
1-Day Range:
$94.81
$97.05
1-Week Range:
$92.79
$102.86
52-Week Range:
$57.77
$112.29
Incyte Corp Stock (INCY) Company Profile
Name
Incyte Corp
Sector
Industry
Phone
(302) 498-6700
Address
1801 AUGUSTINE CUT-OFF, WILMINGTON, DE
Compare INCY vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
INCY
Incyte Corp
|
96.91 | 19.36B | 5.36B | 1.43B | 1.42B | 7.0718 |
VRTX
Vertex Pharmaceuticals Inc
|
423.92 | 107.83B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
701.42 | 73.54B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
783.50 | 48.72B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
296.11 | 39.51B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
293.86 | 32.66B | 5.36B | 287.73M | 924.18M | 2.5229 |
Incyte Corp Stock (INCY) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-16-26 | Downgrade | Jefferies | Buy → Hold |
| Feb-05-26 | Initiated | H.C. Wainwright | Buy |
| Jan-20-26 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Dec-08-25 | Upgrade | Mizuho | Neutral → Outperform |
| Nov-03-25 | Upgrade | Guggenheim | Neutral → Buy |
| Oct-08-25 | Downgrade | Oppenheimer | Outperform → Perform |
| Aug-06-25 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Aug-01-25 | Initiated | Barclays | Overweight |
| Jun-16-25 | Upgrade | Stifel | Hold → Buy |
| Mar-18-25 | Downgrade | Guggenheim | Buy → Neutral |
| Mar-18-25 | Downgrade | William Blair | Outperform → Mkt Perform |
| Dec-17-24 | Initiated | UBS | Neutral |
| Oct-29-24 | Upgrade | BofA Securities | Neutral → Buy |
| Oct-01-24 | Initiated | Wolfe Research | Outperform |
| Sep-18-24 | Downgrade | Truist | Buy → Hold |
| Jul-02-24 | Downgrade | BMO Capital Markets | Market Perform → Underperform |
| May-23-24 | Initiated | Deutsche Bank | Hold |
| Apr-23-24 | Initiated | Cantor Fitzgerald | Neutral |
| Feb-23-24 | Initiated | Jefferies | Buy |
| Feb-14-24 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| Dec-13-23 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Dec-04-23 | Upgrade | Guggenheim | Neutral → Buy |
| Nov-21-23 | Downgrade | Goldman | Buy → Neutral |
| Jul-25-23 | Initiated | Citigroup | Buy |
| May-04-23 | Downgrade | BofA Securities | Buy → Neutral |
| Apr-10-23 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Mar-24-23 | Upgrade | SVB Securities | Underperform → Market Perform |
| Jan-31-23 | Initiated | Piper Sandler | Overweight |
| Aug-03-22 | Downgrade | Evercore ISI | Outperform → In-line |
| Aug-03-22 | Downgrade | Guggenheim | Buy → Neutral |
| Jul-28-22 | Initiated | Wells Fargo | Equal Weight |
| Feb-09-22 | Downgrade | SVB Leerink | Mkt Perform → Underperform |
| Jan-18-22 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Nov-19-21 | Initiated | BMO Capital Markets | Market Perform |
| Jul-20-21 | Upgrade | The Benchmark Company | Hold → Buy |
| Feb-10-21 | Downgrade | SVB Leerink | Mkt Perform → Underperform |
| Jan-07-21 | Initiated | Truist | Buy |
| Jan-04-21 | Upgrade | Guggenheim | Neutral → Buy |
| Jun-16-20 | Initiated | The Benchmark Company | Hold |
| May-06-20 | Downgrade | JP Morgan | Overweight → Neutral |
| Apr-29-20 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Apr-01-20 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Mar-24-20 | Resumed | William Blair | Outperform |
| Mar-13-20 | Upgrade | BofA/Merrill | Neutral → Buy |
| Feb-04-20 | Resumed | BofA/Merrill | Neutral |
| Jan-03-20 | Reiterated | BMO Capital Markets | Market Perform |
| Jan-03-20 | Downgrade | Mizuho | Buy → Neutral |
| Jan-02-20 | Downgrade | Guggenheim | Buy → Neutral |
| Oct-03-19 | Initiated | Mizuho | Buy |
| Sep-12-19 | Initiated | BMO Capital Markets | Market Perform |
| Sep-05-19 | Upgrade | JMP Securities | Mkt Perform → Mkt Outperform |
| Sep-05-19 | Resumed | Morgan Stanley | Equal-Weight |
| Sep-05-19 | Upgrade | Oppenheimer | Perform → Outperform |
| May-21-19 | Initiated | Credit Suisse | Neutral |
| May-03-19 | Downgrade | Barclays | Overweight → Equal Weight |
| Apr-11-19 | Initiated | Stifel | Hold |
| Apr-03-19 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Jan-24-19 | Upgrade | William Blair | Mkt Perform → Outperform |
View All
Incyte Corp Stock (INCY) Latest News
Australia approves new therapy for transplant patients with chronic GVHD - Stock Titan
Incyte to Present Phase 3 Tafasitamab Data at ASCO Meeting - MyChesCo
Incyte Corporation (NASDAQ:INCY) Receives Consensus Rating of "Hold" from Brokerages - MarketBeat
Incyte (INCY) Positioned to Offset Patent Cliff Risks, Analysts Reaffirm Stock Ratings - Insider Monkey
Sanctuary Advisors LLC Has $3.16 Million Holdings in Incyte Corporation $INCY - MarketBeat
Incyte Announces FDA Approval of Jakafi XR™ (ruxolitinib) Extende - The National Law Review
Incyte gears up to report Q1 earnings: What can investors expect? - MSN
Incyte (INCY) Gains FDA Approval for Jakafi XR Treatment - GuruFocus
FDA approves Incyte’s once-daily Jakafi XR formulation - Investing.com
Incyte Announces FDA Approval of Jakafi XR™ (ruxolitinib) Extended-Release Tablets for the Treatment of Myelofibrosis, Polycythemia Vera and Graft-Versus-Host Disease - Business Wire
Incyte Corp. stock outperforms competitors on strong trading day - MarketWatch
Incyte: Strong Business, But Risks Remain (NASDAQ:INCY) - Seeking Alpha
Earnings Beat: Incyte Corporation Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models - Yahoo Finance
INCY Q1 earnings and revenues beat estimates on higher product sales - MSN
INCY SWOT Analysis: Strong Financial Performance Revealed in 10-Q Filing - GuruFocus
Incyte Corp. stock underperforms Thursday when compared to competitors - MarketWatch
Vanguard Capital Management (INCY) discloses 6.32% ownership in Incyte Corp - Stock Titan
GC Wealth Management RIA LLC Takes Position in Incyte Corporation $INCY - MarketBeat
Vanguard Group Inc. Sells 40,189 Shares of Incyte Corporation $INCY - MarketBeat
INCY Maintained by Oppenheimer -- Price Target Raised to $90 - GuruFocus
Stifel raises Incyte stock price target to $123 on earnings beat By Investing.com - Investing.com India
Stifel raises Incyte stock price target to $123 on earnings beat - Investing.com Australia
Incyte to Present at Upcoming May 2026 Investor Conferences - BioSpace
Q4 2025 Incyte Corp Earnings Call Transcript - GuruFocus
INCY Maintained by Stifel -- Price Target Raised to $123 - GuruFocus
Stifel Nicolaus Increases Incyte (NASDAQ:INCY) Price Target to $123.00 - MarketBeat
H.C. Wainwright reiterates Incyte stock rating on Jakafi outlook - Investing.com
Incyte Corporation (NASDAQ:INCY) Q1 2026 Earnings Call Transcript - Insider Monkey
Incyte to Present at Upcoming Investor Conferences - Yahoo Finance
Incyte Corp (INCY) Q1 2026 Earnings Call Highlights: Strong Revenue Growth and Promising Pipeline Developments - GuruFocus
Latest INCY NewsBaricitinib has Significant Effect on Recov... - Stock Titan
INCY Financials: Income Statement, Balance Sheet & Cash Flow | Incyte Corp - Stock Titan
Morgan Stanley raises Incyte stock price target on solid results By Investing.com - Investing.com Nigeria
Oppenheimer raises Incyte stock price target on earnings beat By Investing.com - Investing.com South Africa
Oppenheimer raises Incyte stock price target on earnings beat - Investing.com
Morgan Stanley raises Incyte stock price target on solid results - Investing.com UK
Incyte Welcomes Suky Upadhyay as EVP, CFO - Contract Pharma
[ARS] INCYTE CORP SEC Filing - Stock Titan
Incyte (NASDAQ: INCY) posts 2025 growth, outlines pipeline and pay plan - Stock Titan
Robust Q1 2026 growth at Incyte (NASDAQ: INCY) driven by key drug sales - Stock Titan
TD Cowen raises Incyte stock price target to $124 on demand outlook - Investing.com
Incyte (INCY) Reports Strong Q1 2026 Sales Growth and Strategic Developments - GuruFocus
Incyte (INCY) Q1 2026 Earnings Call Transcript - The Globe and Mail
Incyte (INCY) Q2 2025 Earnings Transcript - The Globe and Mail
Incyte Corporation Q1 2026 Earnings Call Summary - Yahoo Finance
Incyte (INCY) Exceeds Q1 2026 Earnings Expectations with Strong Drug Demand - GuruFocus
Incyte Appoints Suketu (Suky) Upadhyay as Chief Financial Officer - BioSpace
Incyte Reports First Quarter 2026 Financial Results and Provides Business Updates - BioSpace
INCY Q1 Earnings and Revenues Beat Estimates on Higher Product Sales - Yahoo Finance
Incyte (NASDAQ:INCY) Announces Earnings Results, Beats Expectations By $0.47 EPS - MarketBeat
Incyte Q1 Earnings Call Highlights - MarketBeat
Incyte Corp Stock (INCY) Financials Data
Revenue
Net Income
Cash Flow
EPS
Incyte Corp Stock (INCY) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| CAGNONI PABLO J | President, Global Head of R&D |
Apr 17 '26 |
Sale |
96.50 |
18,667 |
1,801,366 |
262,692 |
| Meury William | Chief Executive Officer |
Apr 15 '26 |
Option Exercise |
0.00 |
125,000 |
0 |
161,101 |
2.45%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):